KDMN - Kadmon files US application for belumosudil in GVHD

Kadmon (KDMN) has submitted a marketing application with the FDA for belumosudil (KD025), Rho-associated coiled-coil kinase 2 inhibitor, for the treatment of patients with chronic graft-versus-host disease (cGVHD).The FDA has granted Breakthrough Therapy Designation to belumosudil for the treatment of patients with cGVHD, who failed two or more lines of systemic therapy.The drug candidate is also in Phase 2 trial in adults with diffuse cutaneous systemic sclerosis (KD025-209).

For further details see:

Kadmon files US application for belumosudil in GVHD